{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:20Z","timestamp":1792979900656,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-004713"],"award-info":[{"award-number":["INV-004713"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Africa bears the highest double burden of HIV and malaria worldwide. In 2023, an estimated 25.9 million people were living with HIV (PLHIV), and 246 million malaria cases were diagnosed in Africa. Malaria patients co-infected with HIV are considered at a higher risk of failing malaria treatment, according to the World Health Organization (WHO) guidelines. This systematic literature review aims to assess the treatment outcomes following artemisinin-based combination therapy (ACT) in PLHIV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The literature search was conducted up to April 2022 in the following databases: MEDLINE, EMBASE, Web of Science, Cochrane Central, WHO Global Index Medicus, Clinicaltrials.gov, and the WorldWide Antimalarial Resistance Network (WWARN) Clinical Trial Library. Studies describing any malaria treatment outcomes or anti-malarial drug exposure in PLHIV treated for uncomplicated <jats:italic>Plasmodium falciparum<\/jats:italic> malaria infection were eligible for inclusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 26 articles describing 19 studies conducted between 2003 and 2017 in six countries were included in this review; it represented 2850 malaria episodes in PLHIV across various transmission settings. The most studied artemisinin-based combination was artemether-lumefantrine (in 16 studies). PLHIV were treated with various antiretroviral therapy (ART) regimens, namely efavirenz (EFV), nevirapine (NVP), atazanavir-ritonavir (ATVr), lopinavir-ritonavir (LPV\/r), and\/or on prophylaxis with trimethoprim-sulfamethoxazole (TS), or were untreated (in 3 studies). There was no evidence of an increased risk of recrudescence in PLHIV compared to those without HIV. When treated with artemether-lumefantrine, PLHIV receiving LPV\/r had a lower risk of malaria recurrence compared to PLHIV on NVP-based or EFV-based ART, or those without HIV. LPV\/r increased lumefantrine exposure and EFV-treated patients had a reduced exposure to both artemether and lumefantrine; NVP reduced artemether exposure only.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Limited data on ACT outcomes or drug exposure in PLHIV in Africa remains a reality to date, and the effect of antivirals appears inconsistent in the literature. Considering the heterogeneity in study designs, these review\u2019s findings support conducting an individual patient data meta-analysis to explore the impact of antiretroviral therapy on anti-malarial treatment.<\/jats:p>\n            <jats:p>\n              <jats:italic>Trial registration<\/jats:italic>: The protocol for the original search was published on PROSPERO with registration number CRD42018089860.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12936-025-05393-8","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:47:25Z","timestamp":1747388845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review"],"prefix":"10.1186","volume":"24","author":[{"given":"Abena","family":"Takyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboubakar","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Przybylska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Harriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen I.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabin","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe J.","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia","family":"Stepniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena I.","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"5393_CR1","unstructured":"AIDSinfo. Global data on HIV epidemiology and response 2023 [cited 2025 January, 27]. Available from: http:\/\/aidsinfo.unaids.org\/."},{"key":"5393_CR2","first-page":"2024","volume-title":"addressing inequity in the global malaria response","author":"WHO. World malaria report","year":"2024","unstructured":"WHO. World malaria report. addressing inequity in the global malaria response. Geneva: World Health Organization; 2024. p. 2024."},{"key":"5393_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002059","volume":"3","author":"A Takyi","year":"2023","unstructured":"Takyi A, Carrara VI, Dahal P, Przybylska M, Harriss E, Insaidoo G, et al. Characterisation of populations at risk of sub-optimal dosing of artemisinin-based combination therapy in Africa. PLoS Glob Public Health. 2023;3: e0002059.","journal-title":"PLoS Glob Public Health"},{"key":"5393_CR4","first-page":"88","volume":"9","author":"MD Herrero","year":"2007","unstructured":"Herrero MD, Rivas P, Rallon NI, Ramirez-Olivencia G, Puente S. HIV and malaria. AIDS Rev. 2007;9:88\u201398.","journal-title":"AIDS Rev"},{"key":"5393_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1086\/498577","volume":"193","author":"MR Kamya","year":"2006","unstructured":"Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D, et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis. 2006;193:9\u201315.","journal-title":"J Infect Dis"},{"key":"5393_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1086\/498023","volume":"41","author":"C Cohen","year":"2005","unstructured":"Cohen C, Karstaedt A, Frean J, Thomas J, Govender N, Prentice E, et al. Increased prevalence of severe malaria in HIV-infected adults in South Africa. Clin Infect Dis. 2005;41:1631\u20137.","journal-title":"Clin Infect Dis"},{"issue":"2 Suppl","key":"5393_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4269\/ajtmh.2004.71.41","volume":"71","author":"FO ter Kuile","year":"2004","unstructured":"ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg. 2004;71(2 Suppl):41\u201354.","journal-title":"Am J Trop Med Hyg"},{"key":"5393_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1473-3099(11)70031-7","volume":"11","author":"C Flateau","year":"2011","unstructured":"Flateau C, Le Loup G, Pialoux G. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis. 2011;11:541\u201356.","journal-title":"Lancet Infect Dis"},{"key":"5393_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1126\/science.277.5322.112","volume":"277","author":"B Autran","year":"1997","unstructured":"Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112\u20136.","journal-title":"Science"},{"key":"5393_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12879-016-1345-1","volume":"16","author":"T Kredo","year":"2016","unstructured":"Kredo T, Mauff K, Workman L, Van der Walt JS, Wiesner L, Smith PJ, et al. The interaction between artemether-lumefantrine and lopinavir\/ritonavir-based antiretroviral therapy in HIV-1 infected patients. BMC Infect Dis. 2016;16:30.","journal-title":"BMC Infect Dis"},{"key":"5393_CR11","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.1128\/AAC.05130-11","volume":"55","author":"C Nsanzabana","year":"2011","unstructured":"Nsanzabana C, Rosenthal PJ. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother. 2011;55:5073\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"5393_CR12","unstructured":"WHO. Guidelines for malaria, 3 June 2022. Geneva: World Health Organization; 2022."},{"key":"5393_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4269\/ajtmh.19-0706","volume":"103","author":"J Takata","year":"2020","unstructured":"Takata J, Sondo P, Humphreys GS, Burrow R, Maguire B, Hossain MS, et al. The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: a live, open-access database of Plasmodium treatment efficacy trials. Am J Trop Med Hyg. 2020;103:359\u201368.","journal-title":"Am J Trop Med Hyg"},{"key":"5393_CR14","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"5393_CR15","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2008."},{"key":"5393_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"5393_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.","journal-title":"BMJ"},{"key":"5393_CR18","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64:1311\u20136.","DOI":"10.1016\/j.jclinepi.2011.06.004"},{"key":"5393_CR19","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1002\/sim.2864","volume":"26","author":"JP Klein","year":"2007","unstructured":"Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat Med. 2007;26:4505\u201319.","journal-title":"Stat Med"},{"key":"5393_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.","journal-title":"BMC Med Res Methodol"},{"key":"5393_CR21","unstructured":"VassarStats website for statistical computation. Estimation of a sample's mean and variance from its median and range [cited 2023 December, 27]. Available from: http:\/\/vassarstats.net\/median_range.html."},{"key":"5393_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"5393_CR23","unstructured":"Battistini Garcia SA, Zubair M, Guzman N. CD4 cell count and HIV. [Updated 2025 Jan 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513289\/."},{"key":"5393_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1086\/507310","volume":"194","author":"JP Van Geertruyden","year":"2006","unstructured":"Van Geertruyden JP, Mulenga M, Mwananyanda L, Chalwe V, Moerman F, Chilengi R, et al. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis. 2006;194:917\u201325.","journal-title":"J Infect Dis"},{"key":"5393_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1475-2875-13-205","volume":"13","author":"BA Maganda","year":"2014","unstructured":"Maganda BA, Minzi OM, Kamuhabwa AA, Ngasala B, Sasi PG. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. Malar J. 2014;13:205.","journal-title":"Malar J"},{"key":"5393_CR26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/cid\/ciw291","volume":"63","author":"S Parikh","year":"2016","unstructured":"Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, et al. Antiretroviral choice for HIV impacts antimalarial exposure and treatment outcomes in Ugandan children. Clin Infect Dis. 2016;63:414\u201322.","journal-title":"Clin Infect Dis"},{"key":"5393_CR27","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1128\/AAC.02508-12","volume":"57","author":"I Chijioke-Nwauche","year":"2013","unstructured":"Chijioke-Nwauche I, van Wyk A, Nwauche C, Beshir KB, Kaur H, Sutherland CJ. HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection. Antimicrob Agents Chemother. 2013;57:4146\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"5393_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/QAI.0000000000002237","volume":"83","author":"E Hughes","year":"2020","unstructured":"Hughes E, Mwebaza N, Huang L, Kajubi R, Nguyen V, Nyunt MM, et al. Efavirenz-based antiretroviral therapy reduces artemether-lumefantrine exposure for malaria treatment in HIV-infected pregnant women. J Acquir Immune Defic Syndr. 2020;83:140\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5393_CR29","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1128\/AAC.01727-10","volume":"55","author":"WJ Verret","year":"2011","unstructured":"Verret WJ, Arinaitwe E, Wanzira H, Bigira V, Kakuru A, Kamya M, et al. Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria. Antimicrob Agents Chemother. 2011;55:2629\u201335.","journal-title":"Antimicrob Agents Chemother"},{"key":"5393_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/cid\/ciu353","volume":"59","author":"H Wanzira","year":"2014","unstructured":"Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo MK, Conrad M, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis. 2014;59:509\u201316.","journal-title":"Clin Infect Dis"},{"key":"5393_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/cid\/ciu286","volume":"59","author":"A Kakuru","year":"2014","unstructured":"Kakuru A, Achan J, Muhindo MK, Ikilezi G, Arinaitwe E, Mwangwa F, et al. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis. 2014;59:446\u201353.","journal-title":"Clin Infect Dis"},{"key":"5393_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12936-019-2909-5","volume":"18","author":"E Sevene","year":"2019","unstructured":"Sevene E, Banda CG, Mukaka M, Maculuve S, Macuacua S, Vala A, et al. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Malar J. 2019;18:277.","journal-title":"Malar J"},{"key":"5393_CR33","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa1200501","volume":"367","author":"J Achan","year":"2012","unstructured":"Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012;367:2110\u20138.","journal-title":"N Engl J Med"},{"key":"5393_CR34","doi-asserted-by":"crossref","unstructured":"Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, et al. Parasite clearance and artemether pharmacokinetics parameters over the course of artemether-lumefantrine treatment for malaria in human immunodeficiency virus (HIV)-infected and HIV-uninfected Ugandan children. Open Forum Infect Dis. 2016;3:ofw217.","DOI":"10.1093\/ofid\/ofw217"},{"key":"5393_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1475-2875-13-32","volume":"13","author":"MK Muhindo","year":"2014","unstructured":"Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukan F, et al. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J. 2014;13:32.","journal-title":"Malar J"},{"key":"5393_CR36","doi-asserted-by":"publisher","first-page":"736","DOI":"10.4269\/ajtmh.12-0654","volume":"88","author":"A Kakuru","year":"2013","unstructured":"Kakuru A, Jagannathan P, Arinaitwe E, Wanzira H, Muhindo M, Bigira V, et al. The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children. Am J Trop Med Hyg. 2013;88:736\u201343.","journal-title":"Am J Trop Med Hyg"},{"key":"5393_CR37","first-page":"187","volume":"7","author":"D Musoke","year":"2012","unstructured":"Musoke D, Bergmann TK, Ntale M, Sodemann M, Ogwal-Okeng J. Pharmacokinetics of lumefantrine in adults co-infected with malaria and HIV-1: with and without efavirenz-based antiretroviral therapy. Int J Trop Med. 2012;7:187\u201392.","journal-title":"Int J Trop Med"},{"key":"5393_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12936-015-0695-2","volume":"14","author":"BA Maganda","year":"2015","unstructured":"Maganda BA, Ngaimisi E, Kamuhabwa AA, Aklillu E, Minzi OM. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Malar J. 2015;14:179.","journal-title":"Malar J"},{"key":"5393_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/cpt.104","volume":"98","author":"NC Sambol","year":"2015","unstructured":"Sambol NC, Yan L, Creek DJ, McCormack SA, Arinaitwe E, Bigira V, et al. Population pharmacokinetics of piperaquine in young Ugandan children treated with dihydroartemisinin-piperaquine for uncomplicated malaria. Clin Pharmacol Ther. 2015;98:87\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"5393_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186589","volume":"12","author":"L Huang","year":"2017","unstructured":"Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, et al. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. PLoS ONE. 2017;12: e0186589.","journal-title":"PLoS ONE"},{"key":"5393_CR41","unstructured":"UNAIDS. In danger: UNAIDS global AIDS update 2022. Geneva: Joint United Nations Programme on HIV\/AIDS; 2022."},{"key":"5393_CR42","unstructured":"WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021."},{"key":"5393_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1475-2875-9-177","volume":"9","author":"AF Gasasira","year":"2010","unstructured":"Gasasira AF, Kamya MR, Ochong EO, Vora N, Achan J, Charlebois E, et al. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J. 2010;9:177.","journal-title":"Malar J"},{"key":"5393_CR44","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1097\/QAD.0b013e3282ef6da1","volume":"21","author":"MR Kamya","year":"2007","unstructured":"Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007;21:2059\u201366.","journal-title":"AIDS"},{"key":"5393_CR45","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1086\/529192","volume":"46","author":"AF Gasasira","year":"2008","unstructured":"Gasasira AF, Kamya MR, Achan J, Mebrahtu T, Kalyango JN, Ruel T, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis. 2008;46:985\u201391.","journal-title":"Clin Infect Dis"},{"key":"5393_CR46","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1097\/01.aids.0000247572.95880.92","volume":"20","author":"K Hewitt","year":"2006","unstructured":"Hewitt K, Steketee R, Mwapasa V, Whitworth J, French N. Interactions between HIV and malaria in non-pregnant adults: evidence and implications. AIDS. 2006;20:1993\u20132004.","journal-title":"AIDS"},{"key":"5393_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.actatropica.2016.03.019","volume":"159","author":"LR Smart","year":"2016","unstructured":"Smart LR, Orgenes N, Mazigo HD, Minde M, Hokororo A, Shakir M, et al. Malaria and HIV among pediatric inpatients in two Tanzanian referral hospitals: a prospective study. Acta Trop. 2016;159:36\u201343.","journal-title":"Acta Trop"},{"key":"5393_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.656938","volume":"11","author":"A Roberds","year":"2021","unstructured":"Roberds A, Ferraro E, Luckhart S, Stewart VA. HIV-1 impact on malaria transmission: a complex and relevant global health concern. Front Cell Infect Microbiol. 2021;11: 656938.","journal-title":"Front Cell Infect Microbiol"},{"key":"5393_CR49","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"5393_CR50","unstructured":"WHO. Strategy to respond to antimalarial drug resistance in Africa. Geneva: World Health Organization; 2022."},{"key":"5393_CR51","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1093\/jac\/dks207","volume":"67","author":"P Byakika-Kibwika","year":"2012","unstructured":"Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H, et al. Significant pharmacokinetic interactions between artemether\/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67:2213\u201321.","journal-title":"J Antimicrob Chemother"},{"key":"5393_CR52","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/jac\/dkr596","volume":"67","author":"P Byakika-Kibwika","year":"2012","unstructured":"Byakika-Kibwika P, Lamorde M, Okaba-Kayom V, Mayanja-Kizza H, Katabira E, Hanpithakpong W, et al. Lopinavir\/ritonavir significantly influences pharmacokinetic exposure of artemether\/lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67:1217\u201323.","journal-title":"J Antimicrob Chemother"},{"key":"5393_CR53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/QAI.0b013e3181acb4ff","volume":"51","author":"P German","year":"2009","unstructured":"German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, et al. Lopinavir\/ritonavir affects pharmacokinetic exposure of artemether\/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009;51:424\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5393_CR54","first-page":"95","volume":"144","author":"SO Usman","year":"2020","unstructured":"Usman SO, Oreagba IA, Akinyede AA, Agbaje EO, Akinleye MO, Onwujuobi AG, et al. Effect of nevirapine, efavirenz and lopinavir\/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital. Nigeria J Pharmacol Sci. 2020;144:95\u2013101.","journal-title":"Nigeria J Pharmacol Sci"},{"key":"5393_CR55","doi-asserted-by":"publisher","first-page":"e02394","DOI":"10.1128\/AAC.02394-19","volume":"64","author":"J Francis","year":"2020","unstructured":"Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, et al. An individual participant data population pharmacokinetic meta-analysis of drug-drug interactions between lumefantrine and commonly used antiretroviral treatment. Antimicrob Agents Chemother. 2020;64:e02394-e2419.","journal-title":"Antimicrob Agents Chemother"},{"key":"5393_CR56","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1093\/jac\/dkab022","volume":"76","author":"AN Kawuma","year":"2021","unstructured":"Kawuma AN, Walimbwa SI, Pillai GC, Khoo S, Lamorde M, Wasmann RE, et al. Dolutegravir pharmacokinetics during co-administration with either artemether\/lumefantrine or artesunate\/amodiaquine. J Antimicrob Chemother. 2021;76:1269\u201372.","journal-title":"J Antimicrob Chemother"},{"key":"5393_CR57","first-page":"e01310","volume":"63","author":"SI Walimbwa","year":"2019","unstructured":"Walimbwa SI, Lamorde M, Waitt C, Kaboggoza J, Else L, Byakika-Kibwika P, et al. Drug Interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine. Antimicrob Agents Chemother. 2019;63:e01310-e1318.","journal-title":"Antimicrob Agents Chemother"},{"key":"5393_CR58","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/tpj.2015.37","volume":"16","author":"BA Maganda","year":"2016","unstructured":"Maganda BA, Minzi OM, Ngaimisi E, Kamuhabwa AA, Aklillu E. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. Pharmacogenomics J. 2016;16:88\u201395.","journal-title":"Pharmacogenomics J"},{"key":"5393_CR59","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1086\/647946","volume":"49","author":"E Arinaitwe","year":"2009","unstructured":"Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis. 2009;49:1629\u201337.","journal-title":"Clin Infect Dis"},{"key":"5393_CR60","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/1475-2875-8-258","volume":"8","author":"JP Van Geertruyden","year":"2009","unstructured":"Van Geertruyden JP, Van Eijk E, Yosaatmadja F, Kasongo W, Mulenga M, D\u2019Alessandro U, et al. The relationship of Plasmodium falciparum humeral immunity with HIV-1 immunosuppression and treatment efficacy in Zambia. Malar J. 2009;8:258.","journal-title":"Malar J"},{"key":"5393_CR61","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00228-021-03116-x","volume":"77","author":"SO Usman","year":"2021","unstructured":"Usman SO, Oreagba IA, Kadri MR, Adewumi OO, Akinyede A, Agbaje EO, et al. Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital. South-Western Nigeria Eur J Clin Pharmacol. 2021;77:1341\u20138.","journal-title":"South-Western Nigeria Eur J Clin Pharmacol"},{"key":"5393_CR62","doi-asserted-by":"publisher","first-page":"e01252","DOI":"10.1128\/AAC.01252-18","volume":"62","author":"A Adegbola","year":"2018","unstructured":"Adegbola A, Abutaima R, Olagunju A, Ijarotimi O, Siccardi M, Owen A, et al. Effect of pregnancy on the pharmacokinetic interaction between efavirenz and lumefantrine in HIV-malaria coinfection. Antimicrob Agents Chemother. 2018;62:e01252-e1318.","journal-title":"Antimicrob Agents Chemother"},{"key":"5393_CR63","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/FPC.0000000000000401","volume":"30","author":"AJ Adegbola","year":"2020","unstructured":"Adegbola AJ, Rana A, Adeagbo BA, Bolarinwa RA, Olagunju AE, Siccardi M, et al. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. Pharmacogenet Genomics. 2020;30:96\u2013106.","journal-title":"Pharmacogenet Genomics"},{"key":"5393_CR64","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12936-019-2818-7","volume":"18","author":"CG Banda","year":"2019","unstructured":"Banda CG, Chaponda M, Mukaka M, Mulenga M, Hachizovu S, Kabuya JB, et al. Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial. Malar J. 2019;18:180.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05393-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:02:14Z","timestamp":1747393334000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05393-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5393"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05393-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}